Litigation Details for Snipe v. Gilead Sciences, Inc. (N.D. Cal. 2019)

✉ Email this page to a colleague

Docket	⤷ Sign Up	Date Filed	2019-05-20
Court	District Court, N.D. California	Date Terminated
Cause	15:1 Antitrust Litigation	Assigned To
Jury Demand	Plaintiff	Referred To
Patents	6,043,230; 6,642,245; 6,703,396; 7,390,791; 7,803,788; 8,754,065; 9,296,769
Link to Docket	External link to docket

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

The biologic drug covered by the patents cited in this case is ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2019-05-20	1	Complaint	5,935,946; 5,977,089; and 6,043,230 (the “TDF Patents”). Teva asserted that the TDF patents 23 were invalid…listed patent(s) and/or the patent is invalid and 18 unenforceable. Simply by listing the patents in the…ANDA applicant for patent 23 infringement. If the brand manufacturer brings a patent infringement action…legitimate patent protection or ferret out invalid, unenforceable, or 24 narrow drug patents. 25 …even after the 21 patents on them expired. 22 86. Gilead’s patents on TDF, FTC, and TDF	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document